This could justify experimental therapeutic attempts with clinically available Ca2+ channel blockers in the patient described here as well as the other patients harbouring gain-of-function mutations in CACNA1D. An example of such a successful individualized approach has recently been reported, demonstrating improvement of ASD symptoms and epilepsy in an individual with TSC2 mutations after treatment with everolimus (6). This evidence concerns the gene TSC2 and epilepsy.